Dalpiciclib
- Generic Name
- Dalpiciclib
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N6O2
- CAS Number
- 1637781-04-4
- Unique Ingredient Identifier
- 5ZHA5P4PFX
A Trial of SHR6390 in Healthy Caucasian Volunteers
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Atridia Pty Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04301804
- Locations
- 🇦🇺
Linear Clinical Research, Melbourne, Western Australia, Australia
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT04293276
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
- Conditions
- Breast CancerHER2-positive Breast CancerER-positive Breast Cancer
- Interventions
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT04236310
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
- Conditions
- Metastatic Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Jinming Yu
- Target Recruit Count
- 60
- Registration Number
- NCT04095390
- Locations
- 🇨🇳
Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT03927456
- Locations
- 🇨🇳
Chinese Academy of Medical Science, Beijing, Beijing, China
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 59
- Registration Number
- NCT03772353
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 41
- Registration Number
- NCT03601598
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT03481998
- Locations
- 🇨🇳
Ha'erbin Tumor Hospital, Ha'erbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Peking University
- Target Recruit Count
- 40
- Registration Number
- NCT03480256
- Locations
- 🇨🇳
Department of GI Oncology, Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study of SHR6390 in Advanced Solid Tumor Patients
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02684266
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.